MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy

• Published in: Chinese medical journal Vol. 134; no. 1; pp. 8 - 19
• Main Authors: Xian, Ying-Xin, Weng, Jian-Ping, Xu, Fen
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins 14.12.2020; Lippincott Williams & Wilkins Ovid Technologies; Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China%Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, Guangdong 510630, China%Department of Endocrinology of the First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China; Wolters Kluwer
• Subjects: Cytokines; Diabetes; Drug therapy; Epidemiology; Etiology; Fatty liver; Hepatitis; Hyperglycemia; Insulin resistance; Liver diseases; Metabolic disorders; Metabolic syndrome; Obesity; Pathogenesis; Pathophysiology; Review; China; Pharmacotherapy; Nonalcoholic fatty liver disease; Diagnosis; Pathophysiology; Metabolic (dysfunction) associated fatty liver disease; Epidemiology

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, placing an increasing burden on human health. NAFLD is a complex multifactorial disease involving genetic, metabolic, and environmental factors. It is closely associated with metabolic syndrome, obesity, and...